|
gptkbp:instanceOf
|
gptkb:chemical_compound
platinum-based chemotherapy drug
|
|
gptkbp:approvalYear
|
2002
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01XA03
|
|
gptkbp:CASNumber
|
61825-94-3
|
|
gptkbp:chemicalFormula
|
C8H14N2O4Pt
|
|
gptkbp:color
|
white to off-white powder
|
|
gptkbp:combinationTherapy
|
gptkb:FOLFOX_regimen
|
|
gptkbp:contraindication
|
hypersensitivity to platinum compounds
|
|
gptkbp:discoveredBy
|
gptkb:Yves_Kidani
|
|
gptkbp:drugClass
|
alkylating agents
|
|
gptkbp:eliminationHalfLife
|
9-25 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:firstSynthesized
|
1976
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
oxaliplatin
|
|
gptkbp:indication
|
adjuvant treatment of stage III colon cancer
advanced colorectal cancer
|
|
gptkbp:IUPACName
|
(SP-4-2)-[1R,2R]-cyclohexane-1,2-diamine]oxalatoplatinum(II)
|
|
gptkbp:KEGGID
|
D01857
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Sanofi
|
|
gptkbp:mechanismOfAction
|
DNA crosslinking
|
|
gptkbp:meltingPoint
|
>200°C
|
|
gptkbp:metabolism
|
non-enzymatic biotransformation
|
|
gptkbp:molecularWeight
|
397.29 g/mol
|
|
gptkbp:origin
|
third-generation platinum compound
|
|
gptkbp:patent_expiration
|
2013
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
>85%
|
|
gptkbp:PubChem_CID
|
4456
4617
CHEMBL19045
DB00526
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
peripheral neuropathy
allergic reactions
myelosuppression
|
|
gptkbp:solubility
|
soluble in water
|
|
gptkbp:stable
|
stable under recommended conditions
|
|
gptkbp:storage
|
store at 2-8°C
|
|
gptkbp:synonym
|
gptkb:Eloxatin
trans-L-diaminocyclohexane oxalatoplatinum(II)
|
|
gptkbp:toxicity
|
neurotoxicity
|
|
gptkbp:UNII
|
04ZR38536J
|
|
gptkbp:usedFor
|
treatment of colorectal cancer
|
|
gptkbp:WHO_Essential_Medicines_List
|
included
|
|
gptkbp:bfsParent
|
gptkb:multidrug_resistance-associated_protein_1
|
|
gptkbp:bfsLayer
|
6
|